Dear Robb,

  You said:

<<Hi........I'd like to see an official document showing that the FDA is
indeed trying to do this..........this seems like a hoax to me.  Since when
do they need our approval to do anything?...........anyone have any official
news or proof of this?...........>>



  My post began with a New York Times article with FDA info appended
(official enough?).

  I don't post info without checking the validity first.

   Here is the FDA info once again:


FDA info:


The Office for Human Research Protections (OHRP) and the Food and Drug
Administration (FDA) are soliciting public review and comment on a proposed
research protocol entitled "A Multicenter, Randomized Dose Response Study of
the Safety, Clinical and Immune Responses of Dryvax Administered to Children
2 to 5 Years of Age" as announced in Federal Register Vol. 67, No. 211
Thursday October 31, 2002 Page 66403, available for review on the OHRP
website at:  http://ohrp.osophs.dhhs.gov/dpanel/fr1031.pdf   This proposed
research would include children as research subjects. Experts in relevant
disciplines have reviewed the protocol, but prior to the Secretary, HHS, and
Commissioner, FDA, making a final determination on whether this clinical
investigation may proceed, public review and comment are hereby solicited
pursuant to HHS regulations at 45 CFR 46.407 and FDA regulations at 21 CFR
50.54.   Materials are available for review on the OHRP website at:
http://ohrp.osophs.dhhs.gov/dpanel/dpindex.htm   Public comment on the
proposed research protocol should be submitted to:
http://www.fda.gov/dockets/ecomments   Received comments may be viewed on
the FDA website at:
http://www.fda.gov/ohrms/dockets/dockets/02n0466/02n0466.htm

Regards,
Catherine





--
The silver-list is a moderated forum for discussion of colloidal silver.

Instructions for unsubscribing may be found at: http://silverlist.org

To post, address your message to: [email protected]

Silver-list archive: http://escribe.com/health/thesilverlist/index.html

List maintainer: Mike Devour <[email protected]>